Clal Biotechnology Industries

About The Fund

Clal Biotechnology Industries (CBI) is a leading Israeli life sciences investment firm traded on the Tel Aviv Stock Exchange, specializing in the biotechnology and health-tech sectors. Established in 1998 and headquartered in Tel Aviv, Israel, their primary mission is to identify and empower innovative ventures in the life sciences realm, particularly those developing proprietary solutions that tackle unmet medical needs with significant market potential. The firm's investment approach spans the full range of company maturity, from seed-stage startups to mature public entities, embracing a hands-on leadership style and providing strategic cooperation and substantial investment capital to its portfolio companies. The portfolio under CBI includes a diverse array of biotechnology and medical device companies focused on breakthrough solutions for serious health issues, such as severe burns, chronic wounds, cancer, hematological malignancies, neurology, psychiatry, and thrombosis prevention. Standout portfolio companies include MediWound, specializing in severe burn and wound management; Gamida Cell, a trailblazer in cell and immune therapy; and eXIthera Pharmaceuticals, developing Factor XIa inhibitors with the potential to prevent thrombosis without bleeding liabilities. Additionally, CBI is involved in special-purpose acquisition companies (SPACs), exemplified by their involvement with Cactus Acquisition Corp. 1, which is focused on healthcare-related targets within Israel. Their expertise extends across various investment stages, including seed, Series A, B, and C, up to Pre-IPO rounds, indicating a flexibility and depth of engagement in the venture capital ecosystem. As a VC firm, Clal Biotechnology Industries offers significant value and investment potential through its hands-on approach and strategic guidance to the companies they invest in.